NCT06183983 Hitting the Mark: Introducing State-of-the-art MRI for Precision Radiotherapy of Glioblastoma
| NCT ID | NCT06183983 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Erasmus Medical Center |
| Condition | Glioblastoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 53 participants |
| Start Date | 2024-01-03 |
| Primary Completion | 2025-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 53 participants in total. It began in 2024-01-03 with a primary completion date of 2025-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this prospective cohort study is to assess the potential of advanced MRI for improved radiotherapy target delineation in patients diagnosed with glioblastoma. The main questions it aims to answer are: * How does the coverage of the recurrence volume by a radiotherapy plan based on advanced MRI compare to the coverage by the clinical radiotherapy plan? * How does the distribution of the dose to organs at risk by a radiotherapy plan based on advanced MRI compare to the distribution by the clinical radiotherapy plan? Participants will undergo an extended MRI-protocol prior to radiotherapy. This extended MRI-protocol includes the clinical brain tumor imaging protocol plus additional advanced MRI-sequences. Radiation treatment and patient follow-up will occur according to the clinical standard.
Eligibility Criteria
Inclusion Criteria: * Written informed consent; * Adult (18 years or older); * Diagnosed with IDH-wildtype glioblastoma, as confirmed by pathology including molecular analysis post resection/biopsy; * Referred to the outpatient clinic of the Dept. of Radiotherapy to undergo standard treatment with radiotherapy (30x2 Gy or 15x2.67Gy or 10x3.4Gy). Exclusion Criteria: * Contraindication for (3 Tesla) MRI; * Contraindication for use of gadolinium-based contrast agent (e.g. subject having renal deficiency or known allergy); * Referred for treatment of recurrent glioblastoma; * Previous radiotherapy to the brain; * Unable to give informed consent
Contact & Investigator
Alejandra Méndez Romero, MD, PhD
PRINCIPAL INVESTIGATOR
Erasmus Medical Center
Frequently Asked Questions
Who can join the NCT06183983 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glioblastoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06183983 currently recruiting?
Yes, NCT06183983 is actively recruiting participants. Contact the research team at p.l.y.tang@erasmusmc.nl for enrollment information.
Where is the NCT06183983 trial being conducted?
This trial is being conducted at Rotterdam, Netherlands.
Who is sponsoring the NCT06183983 clinical trial?
NCT06183983 is sponsored by Erasmus Medical Center. The principal investigator is Alejandra Méndez Romero, MD, PhD at Erasmus Medical Center. The trial plans to enroll 53 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.